Leerink analyst Paul Matteis says that with phase II data anticipated in May, he believes most investors do not expect the Neurocrine's valbenazine phase II pediatric Tourette's Syndrome trial to generate a statistically significant p-value. But while the study is relatively small, multiple factors suggest that the clinical benefit of valbenazine in pediatric should be larger than that observed in the prior phase II trial in adults, he contends. The analyst is positively inclined on Neurocrine's shares into pediatric Tourette's data, and continues to believe that modest buy side expectations create an opportunity for the stock ahead of the Tardive Dyskinesia launch. Matteis reiterates an Outperform rating and $68 price target on the shares.